New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform
April 16, 2018 09:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, April 16, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its...
Immunovaccine Files Circular for Annual and Special Meeting of Shareholders
April 04, 2018 16:05 ET
|
Immunovaccine Inc.
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 04, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical...
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
March 28, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, March 28, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the first patient has been treated...
Immunovaccine Announces Webcast of R&D Update and Investor Event
March 27, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, March 27, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced today that it will webcast its ‘R&D...
Immunovaccine Announces Year-End 2017 Financial Results
March 20, 2018 17:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, March 20, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, today released its financial and operational...
Immunovaccine Researchers to Present New Preclinical Data at AACR Annual Meeting 2018
March 19, 2018 17:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, March 19, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Company will present research...
Immunovaccine to Host Investor Event on April 10, 2018 in New York City
March 13, 2018 16:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, March 13, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced today that it will host an R&D Update and...
Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies
March 08, 2018 17:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, March 08, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that its Chief Medical Officer,...
Immunovaccine annonce la clôture d’un placement par voie de prise ferme de 14,375 millions de dollars compte tenu de l’option de surallocation intégralement exercée
February 15, 2018 09:00 ET
|
Immunovaccine Inc.
NE PAS DISTRIBUER À DES AGENCES DE TRANSMISSION DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNIS HALIFAX, N.S., 15 févr. 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (« Immunovaccine » ou la...
Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full
February 15, 2018 09:00 ET
|
Immunovaccine Inc.
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, N.S., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Corporation”)...